Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial

• Published in: PloS one Vol. 9; no. 11; p. e112556
• Main Authors: Brekke, Kristin, Lind, Andreas, Holm-Hansen, Carol, Haugen, Inger Lise, Sørensen, Birger, Sommerfelt, Maja, Kvale, Dag
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 14.11.2014; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; Administration, Intranasal; AIDS; AIDS vaccines; AIDS Vaccines - administration & dosage; AIDS Vaccines - pharmacology; Analysis; Antibodies; Antigens; Biology and Life Sciences; Bone morphogenetic proteins; CD4 antigen; CD8 antigen; Control; Cytokines; Dose-Response Relationship, Immunologic; Drug resistance; Enzyme-Linked Immunosorbent Assay; Health aspects; HIV; Hospitals; Human immunodeficiency virus; Humans; Immune response; Immunity; Immunity, Mucosal - drug effects; Immunity, Mucosal - immunology; Immunogenicity; Immunoglobulin A; Immunoglobulin G; Immunoglobulins; Immunoregulation; In vivo methods and tests; Infections; Infectious diseases; Interleukin 10; Interleukin-10 - immunology; Intranasal administration; Lactoferrin; Lymphocytes; Lymphocytes T; Mucosal immunity; Peptides; Public health; Randomization; Rectum; Secretions; Skin; Skin tests; Statistics, Nonparametric; T cell receptors; T cells; Transforming Growth Factor beta - immunology; Transforming growth factors; Vaccination; Vaccines; Viral Load - drug effects; Norway

Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Safety and immunogenicity were tested in patient...